Identification of the Treatment Pathway of Metastatic Castrate-Resistant Prostate Cancer in Scotland: A Chart Review

Identification of the Treatment Pathway of Metastatic Castrate-Resistant Prostate Cancer in Scotland: A Chart Review

2013 Value in health

Maman, K. | Khemiri, A. | Roiz, J. | Naidoo, S. | Baskin-Bey, E. | Holmstrom, S. | Volume: 16, Issue: 7, Pages: A431,

Chemotherapy with docetaxel was the first therapy approved for the treatment of metastatic Castrate-Resistant Prostate Cancer (mCRPC) while others came along rather recently. With all the treatment options available now, current treatment strategies to appropriately sequence these agents are not known. This study aims to describe mCRPC current treatment paradigms, with specific attention to docetaxel, in Scotland.